Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop and Commercialize Ensifentrine in Greater China
Shots:
- Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech- and is eligible to receive ~$179M in milestones along with royalties on net sales in Greater China (mainland China- Taiwan- Hong Kong and Macau)
- Verona Pharma granted Nuance Pharma exclusive right to develop & commercialize ensifentrine in Greater China and is currently evaluating the therapy in P-III program for COPD in US- EU & South Korea
- Nuance Pharma will be responsible for all costs related to clinical development & commercialization and plans to file a CT Application with CFDA in 2021 & starts clinical studies for COPD in Greater China thereafter
| Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com